In the past decades, end-stage renal disease (ESRD), diators of inflammatory injury in arthritis and other conditions, and COX inhibition by nonsteroidal anti-inflamma-with the consequent demand for renal replacement therapy (RRT), has evolved into a worldwide medical, social, tory drugs (NSAIDs) has been largely employed in the treatment of arthritic patients. There is abundant evi-and financial dilemma, which will likely be aggravated in coming years. Diabetic nephropathy accounts for a dence that COX products mediate inflammation in the kidneys as well. The synthesis of COX products by culti-large fraction of the new cases of ESRD, an unfortunate circumstance considering the high frequency of cardio-vated mesangial cells is enhanced by stretching [2], suggesting that they may mediate hemodynamically induced vascular complications, the early need for RRT, and the high dialysis-related morbidity that afflicts diabetic renal injury. In addition, COX products may participate in several immune and nonimmune cellular mechanisms nephropathy patients.
In view of the magnitude of the current ESRD epidem-of renal injury [3] . Up-regulation of both the COX-1 and COX-2 isoforms has been described in experimental ics, no effort should be spared in the struggle to arrest or at least slow the progression of diabetic and other glomerulopathies, while the production of COX derivatives is increased in the 5/6 renal ablation model [3] . progressive nephropathies, thus postponing the need for RRT. Available treatments include immunosuppressors Accordingly, NSAID treatment attenuated renal injury in the 5/6 renal ablation model without lowering glomer-(mostly, but not exclusively, for immune-related nephropathies), dietary protein restriction, and, especially, ular pressure, suggesting a purely anti-inflammatory effect [4]. angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers. Although these treat-Several observations reported by Harris et al in the past 5 years have contributed to elucidate the role of ments have undoubtedly alleviated the social and financial burden imposed by progressive diabetic and nondia-COX-2 in progressive nephropathies. First, these investibetic nephropathies, a substantial fraction of treated gators showed that COX-2 is expressed in the normal patients still progress to ESRD. Clearly, the developrat kidney, particularly at the macula densa region [5] . ment of new renoprotective maneuvers is still badly They next demonstrated that the expression of COX-2 needed.
was up-regulated in the 5/6 renal ablation model and Progressive nephropathies can be initiated by immune that part of the extra COX-2 material located in the dysfunction, glomerular hemodynamic stress, and toxic glomeruli [6] . In rats with aortic coarctation between the aggression, among other mechanisms. In diabetic subrenal arteries, the group showed that COX-2 expression jects, nonenzymatic protein glycation is also likely to was augmented in the ischemic kidney and that adminisplay an important role in the pathogenesis of renal injury.
tration of a selective COX-2 inhibitor, SC58236, attenu-There is mounting evidence that, whatever the mechaated the systemic hypertension and the hyper-reninemia nisms that initiate progressive nephropathies, an inassociated with this model [7] . In rats with 5/6 renal flammatory reaction, involving the recruitment of macroablation, administration of the same compound attenuphages, lymphocytes, fibroblasts and myofibroblasts, is ated proteinuria and prevented glomerulosclerosis as efrequired to extend and propagate the initial insult. Inficiently as enalapril [8] , lending further support to the flammatory cells can be found in the renal tissue prior idea that COX-2 activation plays an important role in to the establishment of glomerular and interstitial injury the pathogenesis of progressive renal injury. in several models of chronic nephropathy, including dia-In continuation of this line of investigation, Cheng et betic nephropathy [1] . Moreover, macrophage depletion al, in a study published in the current issue of Kidney prevents puromycin-induced renal injury, and treatment
International [9], examined a model of experimental diawith the anti-lymphocyte agent, mycophenolate mofetil, betes associated with hypertension, in which streptozoattenuates renal injury in the renal ablation model [1] .
tocin diabetes was combined with deoxycorticosterone Cyclooxygenase (COX) products are well-known me-(DOCA)-salt treatment. In this model, which mimics the quite common clinical association of diabetes and hypertension, glomerular injury progressed at a faster rate than in rats with diabetes or DOCA-salt alone, re- 2002 by the International Society of Nephrology sulting in severe proteinuria and significant glomerulo-failure), have been widely and successfully employed in the management of progressive nephropathies. If the sclerosis after 6 weeks. The renal expression of COX-2 was increased, along with that of fibronectin, trans-efficacy of COX-2 inhibitors as renoprotective agents is proven, their clinical use will also have to be governed forming growth factor-beta (TGF-␤) and plasminogenactivator inhibitor (PAI-1), suggesting involvement of by careful individual risk/benefit evaluation. these mediators in the pathogenesis of renal injury in Roberto Zatz and Clarice Kazue Fujihara this model. Cheng et al showed that the administration São Paulo, Brazil of SC58236 to these rats reduced the expression of all the mediators examined and prevented the development Correspondence to Roberto Zatz, M.D., Ph.D. Laborató rio de Fisiopatologia Renal Avenida Doutor Arnaldo, 455, 3-s/3342 01246-903 São of glomerulosclerosis, lending support to the idea that 
